12:00 AM
 | 
Nov 24, 2008
 |  BC Week In Review  |  Company News  |  Other News

Compugen gene/cell therapy, computational chemistry/biology news

Compugen will restructure and reduce headcount by about 22 (30%) to 50 to focus on its drug discovery platforms and preclinical biologics. The company has multiple mAbs and...

Read the full 117 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >